D-0636-2020 Class I Terminated

Recalled by AuroMedics Pharma LLC — East Windsor, NJ

FDA drug recall D-0636-2020 was initiated by AuroMedics Pharma LLC on Nov 20, 2019 and is designated Class I. Reason for recall: Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets. The recall status is terminated (terminated Feb 21, 2024).

Recall Details

Product Type
Drugs
Report Date
Dec 18, 2019
Initiation Date
Nov 20, 2019
Termination Date
Feb 21, 2024
Voluntary/Mandated
Voluntary: Firm initiated

Product Description

Mirtazapine Tablets, USP, 15 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 13107-031-05

Reason for Recall

Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.

Distribution Pattern

Nationwide

Code Information

Lot #: 03119002A3, Exp 3/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0636-2020
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0636-2020. Report a data issue: hello@regdatalab.com.